Drug repurposing investigates an existing drug for a new therapeutic use. It reduces the time, cost, and failure risk of developing treatments by reusing evidence from toxicology, preclinical models, clinical trials, and post-release surveillance. section 4.3
A knowledge-graph repurposing workflow proceeds through these stages:
- Assemble a heterogeneous graph connecting compounds, diseases, genes, pathways, biological processes, anatomy, symptoms, side effects, and pharmacological classes. section 4.3
- Represent each compound–disease pair with metapaths of lengths two to four, including binding, gene association, pathway participation, and anatomy relationships. section 10.2.2
- Count paths and calculate degree-weighted path counts such as DWPC, reducing the influence of highly connected nodes. section 10.2.2
- Train a machine-learning model to translate network connectivity into a probability that a compound treats a disease. section 10.2.2
Metformin and type 2 diabetes
A Cypher query matches metformin to type 2 diabetes mellitus through the Compound–binds–Gene–associates–Disease metapath, counts matching paths, and returns the path count and DWPC. Longer alternatives can traverse anatomy or biological pathways.
